Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Hadaschik

Showing results (161-170 of 269) with videos related to

Pageof 27
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 9, 2018
Biochemical Recurrence of Prostate Cancer: Initial Results with [<sup>18</sup>F]PSMA-1007 PET/CTFrederik L Giesel, Leon Will, Claudia Kesch, et al.
BJU International|November 19, 2016
Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsyNienke L Hansen, Claudia Kesch, Tristan Barrett, et al.
Targeted Oncology|June 29, 2026
Efficacy and Safety Differences Between Abiraterone and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis of Real-World StudiesAnikó Katalin Valikovics, Dániel Bacsó, Nadeen Samaien, et al.
Urologia Internationalis|June 28, 2018
The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate CancerChristopher Darr, Ulrich Krafft, Boris Hadaschik, et al.
European Journal of Radiology|November 30, 2025
Evaluation of the TARGET score for MRI-based detection of prostate cancer recurrence in patients treated with HIFU hemiablationConstantin Ehrengut, Nilüfer Deniz Alberalar, Toni Franz, et al.
Urologic Oncology|May 5, 2019
Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancerUlrich Krafft, Stephan Tschirdewahn, Jochen Hess, et al.
European Urology Oncology|May 14, 2024
Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature ReviewBenjamin A Gartrell, Angaja Phalguni, Paulina Bajko, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 2, 2017
PSMA-11-Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate CancerAnn-Christin Baranski, Martin Schäfer, Ulrike Bauder-Wüst, et al.
Radiation Oncology (London, England)|April 2, 2022
Dosimetric feasibility of moderately hypofractionated/dose escalated radiation therapy for localised prostate cancer with intensity-modulated proton beam therapy using simultaneous integrated boost (SIB-IMPT) and impact of hydrogel prostate-rectum spacerDalia Ahmad Khalil, Danny Jazmati, Dirk Geismar, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 12, 2020
Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging: A Multicenter Retrospective StudyAndrea Farolfi, Nader Hirmas, Andrei Gafita, et al.
Pageof 27

Showing results (161-170 of 269) with videos related to

Sort By:
Pageof 27
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 9, 2018
Biochemical Recurrence of Prostate Cancer: Initial Results with [<sup>18</sup>F]PSMA-1007 PET/CTFrederik L Giesel, Leon Will, Claudia Kesch, et al.
BJU International|November 19, 2016
Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsyNienke L Hansen, Claudia Kesch, Tristan Barrett, et al.
Targeted Oncology|June 29, 2026
Efficacy and Safety Differences Between Abiraterone and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis of Real-World StudiesAnikó Katalin Valikovics, Dániel Bacsó, Nadeen Samaien, et al.
Urologia Internationalis|June 28, 2018
The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate CancerChristopher Darr, Ulrich Krafft, Boris Hadaschik, et al.
European Journal of Radiology|November 30, 2025
Evaluation of the TARGET score for MRI-based detection of prostate cancer recurrence in patients treated with HIFU hemiablationConstantin Ehrengut, Nilüfer Deniz Alberalar, Toni Franz, et al.
Urologic Oncology|May 5, 2019
Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancerUlrich Krafft, Stephan Tschirdewahn, Jochen Hess, et al.
European Urology Oncology|May 14, 2024
Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature ReviewBenjamin A Gartrell, Angaja Phalguni, Paulina Bajko, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 2, 2017
PSMA-11-Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate CancerAnn-Christin Baranski, Martin Schäfer, Ulrike Bauder-Wüst, et al.
Radiation Oncology (London, England)|April 2, 2022
Dosimetric feasibility of moderately hypofractionated/dose escalated radiation therapy for localised prostate cancer with intensity-modulated proton beam therapy using simultaneous integrated boost (SIB-IMPT) and impact of hydrogel prostate-rectum spacerDalia Ahmad Khalil, Danny Jazmati, Dirk Geismar, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 12, 2020
Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging: A Multicenter Retrospective StudyAndrea Farolfi, Nader Hirmas, Andrei Gafita, et al.
Pageof 27